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REVIEW
Abstract: Allergic rhinitis (AR) is a major health problem that can significantly impair quality
of life (QoL). The former classification of AR comprises seasonal allergic rhinitis (SAR) and
perennial allergic rhinitis (PAR), which do not adequately reflect the clinical course and
presentation of AR. The Allergic Rhinitis and its Impact on Asthma (ARIA) classification is
based on the duration of symptoms and their severity. Persistent AR (PER) is experienced for
periods longer than 4 days/week and for more than 4 consecutive weeks, and may feature
mild or moderate-to-severe disease based on the impairment of QoL and symptom severity.
Oral antihistamines are a standard treatment option in AR. New second generation
antihistamines have a rapid onset of action, are highly effective on AR symptoms, and some
were even shown to relieve nasal congestion. Levocetirizine is a potent histamine H1-receptor
antagonist with proven efficacy in both SAR and PAR, and it is the best studied therapeutic
option in persistent AR. The Xyzal in Persistent Rhinitis Trial (XPERT™) studied 551 patients
with PER, showing that levocetirizine (5 mg/day compared with placebo) significantly
improved nasal symptoms as early as the first week and for the 6 months of study, with
significant improvement in nasal congestion after 6 weeks of treatment. Levocetirizine also
improved QoL, was well tolerated, and produced substantial societal and employer cost savings.
Thus, levocetirizine is the first tested standard treatment for PER using ARIA classification,
and shows prompt short-term and long-term relief of symptoms, improves patients’ QoL, and
provides economic benefits to employers and the society.
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Introduction
Allergic rhinitis (AR) is a major health problem with high and ever-increasing
prevalence (Bousquet et al 2001). At least one in five adults in Western Europe are
estimated to have AR (Bauchau and Durham 2004), and its well-known nasal and
eye symptoms can be severe enough to have a substantial negative impact on daily
activities and sleep, with resulting impairment of quality of life (QoL) similar to that
caused by asthma (Bousquet, Bullinger et al 1994; Bousquet, Knani et al 1994).
Despite the debilitating effects of AR, it remains a condition where patients do not
seek appropriate treatment, are undertreated, or do not adhere to treatment; all of
which lead to high societal costs (Malone et al 1997; Schoenwetter et al 2004). A
recent study found a total cost of about €350 per month, mainly due to reduced
productivity, for each AR patient who had not received appropriate long-term therapy
for their condition (Bousquet et al 2005). Therefore, there is a need to radically
improve diagnosis, treatment, and management of AR.
Allergic rhinitis and its impact on asthma
The former classification of AR comprised seasonal allergic rhinitis (SAR), which
was mainly linked to pollen allergy, and perennial allergic rhinitis (PAR), which was
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mainly linked to house-dust mites. Many shortcomings of
this classification have become apparent over the years. For
example, many AR patients are polysensitized to pollen and
perennial allergens (Bauchau and Durham 2005), and thus
cannot be classed as having SAR or PAR. Also, some
countries have seasonal pollen, while others have pollen
for many months, or even perennially (Bousquet et al 2001).
Finally, the SAR/PAR classification does not cover severity
or duration of the disease, which makes it difficult to decide
upon the best treatment option.
The Allergic Rhinitis and its Impact on Asthma (ARIA)
classification system was introduced in 2001 and is based
on duration and severity of symptoms and their impact on
QoL (Figure 1) (Bousquet et al 2001). The duration of AR
is split into intermittent and persistent patterns. Intermittent
AR is defined by symptoms that occur for 4 or less days per
week or for not more than 4 consecutive weeks, whereas
persistent AR (PER) lasts for more than 4 days per week
and for more than 4 consecutive weeks. Symptoms of
intermittent AR or PER may be mild or moderate-to-severe
based on its impact on QoL and symptom severity. Mild
rhinitis characteristically does not affect daily, leisure, or
sport activities, normal work or school attendance, or disturb
sleep, and causes no bothersome symptoms. Moderate-to-
severe rhinitis is characterized by impairment of at least
one of these parameters. Compared with patients with
intermittent AR, PER patients had more severe symptoms,
a higher rate of self awareness, previous diagnosis of AR,
differed in their use of medication, and had a clearly distinct
allergen sensitization pattern (Bauchau and Durham 2005).
The ARIA classification system is distinct from the
classic one. Patients classified as having SAR do not
necessarily have intermittent AR, and PAR-classified
patients do not always have PER (Bauchau and Durham
2005). In one study, nearly half of so-called SAR patients
had PER, and nearly half of PAR patients had only
intermittent AR (Demoly et al 2003; Bauchau and Durham
2005). Another feature of ARIA is that it acknowledges the
relationship of AR with asthma and other comorbidities such
as rhinosinusitis and conjunctivitis, and recommends a
combined treatment strategy of upper and lower airways
for optimum management (Bousquet et al 2001).
PER management
PER is managed on different levels and includes allergen
avoidance, immunotherapy, pharmaceutical treatment, and
patient education (Bousquet et al 2001). Allergen avoidance
measures should always be indicated when possible and
appear to be effective, although the level of scientific
evidence is low (Bousquet et al 2001). Allergen avoidance
can be difficult because patients are often sensitised to many
allergens, and it may impact negatively on daily activities,
family life, and QoL (Martin 1999; Morris 2004). Examples
of avoidance measures include removal of carpets, regular
vacuuming, regular washing of bedclothes, use of dust mite-
resistant covers, removal of pets, and staying inside during
high pollen loads (Bousquet et al 2001; Horak et al 2004;
Peat et al 2004; van den Bemt et al 2004; Simpson and
Custovic 2005).
Allergen immunotherapy may be suitable in PER
patients who have severe or long-term symptoms
predominantly induced by dominating allergens. ARIA
recommends allergen immunotherapy in carefully selected
patients with rhinitis (especially when complicated by
asthma) and specific sensitivities, and in patients in whom
pharmacotherapy produces incomplete symptom control or
undesirable adverse events (Bousquet et al 2001; Durham
et al 1999). It should be initiated early in the disease process
to reduce the risk of adverse events and to prevent the further
development of severe disease as it may alter the course of
disease and prevent asthma. It can be given subcutaneously
and is effective; however, it is time consuming, costly, and
carries a low risk of anaphylaxis (Bousquet et al 2001).
Sublingual administration has a lower risk of anaphylaxis
Figure 1 Allergic Rhinitis and its Impact on Asthma (ARIA). Dark lines show
that moderate-to-severe symptoms occur most often in persistent allergic
rhinitis (PER) with milder symptoms in intermittent allergic rhinitis. Adapted
from Bousquet et al (2001).
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and is less time-consuming than subcutaneous administra-
tion, but it may have lower efficacy and requires good
compliance by the patient (Bousquet et al 2001; Wilson et
al 2005).
Pharmacotherapeutic options include oral anti-
histamines, and topical antihistamines that can be
administered in the nose. According to ARIA, antihistamines
are recommended for all types of intermittent rhinitis and
mild persistent rhinitis; in severe persistent rhinitis,
intranasal steroids are the first-line treatment due to their
higher efficacy in treating nasal obstruction, and they may
be complemented by antihistamines as add-on treatment if
required (Bousquet et al 2003; Simons 2004).
Compared with older antihistamines, newer anti-
histamines have rapid onset of action (minutes to hours),
are easy to use, and are highly effective on symptoms such
as rhinorrhea, sneezing, and nasal and ocular pruritus. They
are mostly free of anticholinergic adverse effects and
relatively safe compared with first generation antihistamines,
even in population groups such as the elderly (Hansen et al
2005). Furthermore, the newer agents are comparatively
nonsedating, thus providing further benefit over older
antihistamines with sedative properties that are no longer
recommended in adults or in children (Kay 2000).
It was shown in PER that local inflammation is closely
linked to nasal obstruction and airflow (Ciprandi et al
2005a). So the antiinflammatory activities exerted by some
modern antihistamines may explain the efficacy on nasal
obstruction and decongestant effects found in some
antihistamines like levocetirizine (Ciprandi et al 2005a). In
addition, antihistamines may reduce symptoms of AR and
asthma in patients with comorbid diseases (Simons 2002,
2004; Bachert and Demarteau 2005). The antiinflammatory
effect of newer antihistamines is gaining significance in
allergic conditions where inflammation might occur and lead
to asthma (Simons 2004). For example, in the Early
Treatment of the Atopic Child (ETACTM) study, the
antihistamine cetirizine has been shown to prevent the atopic
march from atopic dermatitis to asthma in patients sensitized
to grass pollen or house-dust mite (Warner 2001). This
interesting result is being investigated in the Early Prevention
of Asthma in Atopic Children (EPAAC™) study with
levocetirizine (Fumagalli et al 2004).
Nasal steroids are highly effective in reducing
inflammation and nasal symptoms in AR. They are
particularly useful in patients suffering from prominent nasal
obstruction. Compared with antihistamines, however, they
have a slower onset of action (days), and especially beclo-
methasone at high doses, may have a less favourable safety
profile for chronic use in children. Oral steroids are reserved
for very severe cases only, due to serious adverse events
from chronic use. Some patients with concomitant asthma
may need treatment with both inhaled and oral steroids, so
adding a nasal steroid for concomitant rhinitis may not be
the primary choice.
Other treatments include chromones (less effective than
antihistamines or nasal steroids, but valuable in children
and pregnant women in view of their excellent safety
profile), nasal decongestants (symptomatic relief for nasal
obstruction, only for short-term use), and oral decongestants
(may lead to tachycardia, insomnia, anxiety, and may
aggravate prostate problems and glaucoma). Leukotriene-
receptor antagonists may play a role in treating AR patients
with asthma (Bousquet et al 2001); however, the consensus
of two reviews is that they are no more effective in AR than
nonsedating antihistamines and are less effective than nasal
steroids (Nathan 2003; Wilson et al 2004).
The H1-antihistamine
levocetirizine
Levocetirizine is a potent histamine H1-receptor antagonist,
and is the active enantiomer of the racemate, cetirizine
(Tillement et al 2003). Studies in healthy volunteers showed
that it very effectively blocks the histamine wheal and flare
response in human skin, with its potency exceeding those
of other tested substances like desloratadine, fexofenadine,
ebastine, and cetirizine (Clough et al 2001; Devalia et al
2001; Grant et al 2002). In addition to its antihistaminic
effect, levocetirizine also demonstrated antiinflammatory
effects in cell culture studies (Thomson et al 2002;
Giustizieri et al 2004) and in vivo (Michel et al 2001;
Ciprandi et al 2004).
Levocetirizine 5 mg once daily was established as the
most effective and well tolerated dose, producing significant
improvements in AR symptoms compared with placebo in
a study of 470 patients with SAR (Leynadier et al 2001). A
further placebo comparison in 294 patients with PAR
showed it produced rapid and significant improvements in
AR symptoms within the first week of treatment, which were
maintained throughout a 6-week treatment period (Potter
2003). Interestingly, nasal congestion was also significantly
reduced in the levocetirizine group compared with placebo
over the treatment period with significance within the firstTherapeutics and Clinical Risk Management 2005:1(4) 268
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week (p < 0.002), and a relative improvement of 83% over
the 6 weeks of treatment (p < 0.001).
Similar results were found in a placebo-controlled study
of 177 children with SAR where levocetirizine (5 mg/day)
significantly improved ocular and nasal symptoms of AR
within the first week of treatment, with maintained activity
over 6 weeks (de Blic et al 2005). Relief of nasal congestion
was observed in the levocetirizine group throughout the
study, reaching a maximum difference to placebo during
week 3 (p < 0.05) with a relative improvement over placebo
of 78%. This difference was maintained until week 5
(p < 0.05), but during the last week, the difference became
smaller and nonsignificant due to a strong placebo effect.
Concerning QoL measured by PRQLQ (Paediatric
Rhinoconjunctivitis Quality of Life Questionnaire), children
treated with levocetirizine presented larger improvements
in overall and domain scores after 2 weeks, 4 weeks, and 6
weeks of treatment than children under placebo.
Levocetirizine was well tolerated in all of the studies, thus
complementing the reported lack of cognitive and psycho-
motor side effects with this drug (Gandon and Allain 2002).
The efficacy of levocetirizine was tested in various
comparative clinical trials. In placebo-controlled studies in
allergen challenge chambers (Day et al 2004; Stübner et al
2004; Horak et al 2005), it provided better protection from
and relief from symptoms than single-dose desloratadine
5 mg (Day et al 2004; Deruaz et al 2004), or fexofenadine
120 mg (Horak 2005), and it was superior to loratadine
10 mg in improving symptoms in SAR (Stübner et al 2004).
These comparative trial results were corroborated in two
clinical trials in SAR and PAR where levocetirizine showed
better symptom control, increase in nasal airflow, and
antiinflammatory activity than desloratadine (Ciprandi et
al 2004, 2005b).
Ciebiada et al (2005) compared levocetirizine 10 mg
monotherapy with montelukast 10 mg monotherapy,
combined therapy, and placebo over 6 weeks in patients
with PAR. Levocetirizine alone was more effective on nasal
symptoms and inflammatory markers than montelukast
alone; but the combination treatment offered an even better
symptom control. This combined receptor blockade may
be an interesting therapeutic option. This was also shown
by a recent study in SAR patients where levocetirizine 5 mg
alone, montelukast 10 mg alone, combined therapy and
placebo were compared over 2 weeks (Lombardo et al 2005).
Both monotherapies were effective on symptoms, but the
combined treatment was superior on symptoms and QoL.
Levocetirizine in PER
The above studies were performed in a variety of patients
with AR classified by the classic system in SAR and PAR.
It is difficult to guess how this evidence can be translated
into the new indication PER because PER patients are
different from SAR or PAR patients. That is why it is of
clinical relevance to study rhinitis medication in patients
with PER. As of today, few studies have been performed
with antihistamines or nasal steroids in PER, although the
ARIA classification has been adopted by the industry and
academia. Most of these studies were done with levo-
cetirizine. There have been even fewer studies performed
in intermittent rhinitis, and there is no evidence yet for
levocetirizine in this indication.
A pilot study in 40 patients with PER showed that
levocetirizine 5 mg/day for 4 weeks improved nasal
symptoms, including nasal obstruction, and increased total
nasal airflow (Ciprandi et al 2005a). In addition,
levocetirizine showed decongestant effects by decreasing
the reversibility of nasal airflow after application of a potent
alpha-adrenostimulator.
The only major clinical trial to assess any agent as a
standard treatment option for PER is the Xyzal in Persistent
Rhinitis Trial (XPERT™) (Bachert et al 2004), a 6-month,
double-blind, placebo-controlled multicenter trial of 551
patients with PER who received levocetirizine 5 mg/day or
placebo. The study assessed individual symptoms, QoL
(both general and disease-specific), comorbidities,
pharmacoeconomics, and safety (Bachert et al 2004).
Results from XPERT showed that levocetirizine
significantly improved nasal and ocular symptoms compared
with placebo as early as 1 week after starting treatment and
this improvement was maintained over the 6-month period
of study (Figure 2). Notably, significant improvement in
nasal congestion was observed versus placebo after the first
month of treatment and maintained over 6 months (p < 0.05
for months 2–6) (Van Cauwenberge et al 2005), which the
authors attributed to the long-term antiinflammatory action
of levocetirizine (Bachert et al 2004). Levocetirizine also
improved QoL (assessed by Rhinoconjunctivitis Quality of
Life Questionnaire and Short-Form 36), and was well
tolerated (Bachert et al 2004) (Figure 3). An economic
analysis showed the relatively low cost of long-term
levocetirizine therapy compared with the substantial cost
of untreated PER and its comorbidities (€350/patient/
month). Levocetirizine treatment produced cost savings to
society of more than €150/patient/month, mainly due toTherapeutics and Clinical Risk Management 2005:1(4) 269
Levocetirizine in persistent allergic rhinitis
patients being able to maintain work ability and daily
activities (Bousquet et al 2005). In an exploratory analysis
of the XPERT study, levocetirizine reduced the percentage
of patients with at least one asthma event to 7.4 (from 13.6
for placebo, p = 0.04) and reduced the mean number of
asthma medication events from 0.23 per placebo patient to
0.11 (p < 0.001) (Bachert and Demarteau 2005).
Conclusion
ARIA defines AR as intermittent AR or PER, based on
symptom duration and severity. It complements the classic
SAR/PAR classification, and clearly defines PER as different
from PAR. Long-term studies in PER will be able to show
the effect of drug therapy on allergic symptoms, including
nasal congestion. Levocetirizine is currently the best studied
treatment in PER, although studies in intermittent rhinitis
are still lacking. XPERT showed that over a period of 6
months, levocetirizine was effective against PER symptoms
(including nasal congestion), improved QoL, reduced the
incidence of comorbidities like asthma, and reduced societal
costs. These results show that assessment of drug efficacy
and tolerability according to ARIA is clinically relevant,
and that significant benefit may be achieved with long-term
treatment of PER with levocetirizine.
Figure 2 Change in individual symptom scores among 551 patients with persistent allergic rhinitis who received levocetirizine 5 mg/day or placebo over a period of
6 months. Source: Bachert C, Bousquet J, Canonica GW, et al. 2004. Levocetirizine improves quality of life and reduces costs in long-term management of persistent
allergic rhinitis. J Allergy Clin Immunol, 114:838–44. Copyright © 2004 Elsevier, USA. Reproduced with permission from Elsevier.
Figure 3 Summary of Xyzal in Persistent Rhinitis Trial (XPERT™) in patients
with persistent allergic rhinitis (PER).
Efficacy 
Rapid relief from nasal and 
ocular symptoms. 
Prolonged relief over 6 months 
of study, including relief from 
nasal congestion. 
Tolerability 
Safe and well tolerated with 
incidence of adverse events 
same as placebo. 
Economic analysis 
Substantially reduced societal 
costs, mainly due to patients 
being able to stay at work and 
maintain daily activities. 
Reduced costs of treating 
comorbidities such as asthma.
Quality of life 
Lowered disease burden and 
improved quality of life, 
consistent with decrease in 
symptom severity.
XPERT™
Levocetirizine 5 mg/day versus 
placebo over 6 months in 551 
patients with PER Therapeutics and Clinical Risk Management 2005:1(4) 270
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